In This Article:
Medicure (CVE:MPH) Full Year 2024 Results
Key Financial Results
-
Revenue: CA$21.9m (up 1.0% from FY 2023).
-
Net loss: CA$1.04m (loss widened by 13% from FY 2023).
-
CA$0.10 loss per share (further deteriorated from CA$0.088 loss in FY 2023).
Our free stock report includes 2 warning signs investors should be aware of before investing in Medicure. Read for free now.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Medicure's share price is broadly unchanged from a week ago.
Risk Analysis
We should say that we've discovered 2 warning signs for Medicure that you should be aware of before investing here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.